Increased protein expression of cyclin A1 has been substantially associated with the overall survival of ovarian cancer patients, and silencing cyclin A1 improves the chemosensitivity of ovarian cancer cells to paclitaxel (Huang et al., 2016[54]). The gene discussed is CCNA1; the disease is ovarian carcinoma.